Clinical Trials
21 trialsNCT05336409 2025-12-18
ELiPSE-1
Century Therapeutics, Inc.
Phase 1 Terminated
NCT05035407 2025-12-02
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT05385705 2025-09-22
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Vall d'Hebron Institute of Oncology
Phase 1 Terminated
NCT03991741 2025-07-03
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
University of California, San Diego
Phase 1 Terminated
NCT04625205 2025-04-06
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
BioNTech SE
Phase 1 Terminated
NCT04887259 2025-01-27
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Lava Therapeutics
Phase 1 Terminated
NCT03912831 2023-12-26
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
Gilead Sciences
Phase 1 Terminated
NCT04023071 2023-10-26
FT516 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT04551885 2023-09-21
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT01493453 2023-04-19
CD19
The Christie NHS Foundation Trust
Phase 1 Terminated
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT03992326 2021-03-18
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
Centre Hospitalier Universitaire Vaudois
Phase 1 Terminated
NCT02070406 2019-02-28
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT01409174 2017-05-31
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00569296 2015-03-25
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer
Roger Williams Medical Center
Phase 1 Terminated
NCT01081808 2015-03-25
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
Roger Williams Medical Center
Phase 1 Terminated
NCT01404702 2014-12-02
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
University of Alabama at Birmingham
Phase 1 Terminated
NCT00054405 2013-04-09
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00091611 2012-10-26
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01106235 2011-12-21
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1 Terminated